AOD-9604 vs GH Fragments: Lipolysis Research Without Full GH Signaling
Why the hGH 176–191 region was developed for adipose-focused models and how it differs from full-length growth hormone in research expectations.
Background
Full-length human growth hormone (hGH, 191 amino acids) produces a complex set of biological effects: anabolic signaling via hepatic IGF-1 generation, direct metabolic effects on adipose and muscle, diabetogenic effects via insulin resistance, and growth-promoting effects on bone and cartilage. From a research perspective, this broad activity makes hGH an imprecise tool for isolating lipolysis mechanisms.
In the 1990s, researchers identified that the C-terminal region of hGH (residues 176–191) retained lipolytic activity but lacked the anabolic, IGF-1-generating, and glucose-dysregulating effects of the full protein. AOD-9604 is a modified version of this fragment designed for research and eventual therapeutic investigation.
Molecular profile
- Sequence: based on hGH(177–191) with an added N-terminal tyrosine (Tyr-Leu-Arg-Ile-Val-Gln-Cys-Arg-Ser-Val-Glu-Gly-Ser-Cys-Gly-Phe, 16 aa)
- Molecular weight: ~1,817 Da
- Modification: disulfide bond between Cys-7 and Cys-14
- CAS: 221231-10-3
Mechanism
AOD-9604's lipolytic mechanism differs from full-length hGH's:
- Does not activate the growth hormone receptor in standard assays
- Does not elevate IGF-1 in published studies
- Proposed to act through a distinct receptor or mechanism that stimulates hormone-sensitive lipase (HSL) activity in adipocytes
- Upregulates β3-adrenergic receptor expression and responsiveness in some adipose tissue models
- Inhibits lipogenesis in parallel with promoting lipolysis
This mechanistic separation is the scientific rationale for AOD-9604 as a research tool: it allows investigators to probe adipose tissue biology without the confounding anabolic, glycemic, and growth-promoting effects of full hGH.
What laboratories typically study
- Adipocyte lipolysis assays — free fatty acid release from 3T3-L1 or primary adipocytes
- Hormone-sensitive lipase activity — phospho-HSL immunoblots, enzymatic assays
- Adipogenesis and lipogenesis — preadipocyte differentiation, lipid accumulation (Oil Red O), lipogenic gene expression (FAS, ACC, SREBP1c)
- β-adrenergic receptor biology — receptor density, coupling efficiency, catecholamine response
- Obesity models — DIO rodent adipose tissue characterization, metabolic parameters without confounding IGF-1 elevation
- Comparative pharmacology — AOD-9604 vs recombinant hGH on lipolysis-specific endpoints
- Cartilage research — some studies explore fragment effects on chondrocyte biology independent of systemic IGF-1
What AOD-9604 is not
Worth clarifying given marketing claims in non-research contexts:
- Not equivalent to hGH — lacks IGF-1-generating and anabolic effects
- Not a GH secretagogue — does not stimulate pituitary GH release
- Not a myostatin inhibitor or direct muscle-growth agent
Its research value is specifically its adipose-selective profile.
Handling and quality
- Supplied as lyophilized powder (typical format 5 mg)
- Store lyophilized at -20°C, protected from light
- Reconstitute with sterile/bacteriostatic water
- Disulfide bond integrity is important — avoid harsh reducing conditions during reconstitution
- Reconstituted stability ~4 weeks at 2–8°C
- Verify by HPLC (≥99.0%) with MS identity; obtain batch-specific COA
Related reading
- /research/aod-9604 — compound profile
- /blog/aod-9604-precision-lipolysis-research — focused AOD-9604 overview
- /category/weight-loss-research — broader category
- /guides/how-to-read-peptide-coa — batch documentation
RUO disclaimer
For laboratory research use only. Not intended to diagnose, treat, cure, or prevent any disease. Not for human consumption outside approved research settings.